Obesity definition for personalised treatment of type 2 diabetes Authors’ reply

Ildiko Lingvay; Priya Sumithran; Ricardo V. Cohen; Carel W.le Roux

doi:10.1016/S0140-6736(22)00890-X

Obesity definition for personalised treatment of type 2 diabetes Authors’ reply

Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, Carel W.le Roux

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2189-2190
Number of pages	2
Journal	The Lancet
Volume	399
Issue number	10342
DOIs	https://doi.org/10.1016/S0140-6736(22)00890-X
State	Published - Jun 11 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/S0140-6736(22)00890-X

Cite this

@article{9448079ab6a04f27bbbed209e260be3e,

title = "Obesity definition for personalised treatment of type 2 diabetes Authors{\textquoteright} reply",

author = "Ildiko Lingvay and Priya Sumithran and Cohen, {Ricardo V.} and Roux, {Carel W.le}",

note = "Funding Information: IL received grants (paid to their institution), consulting fees, other payments (including for participation in meetings, such as steering committees; advisory boards; and presentations at national and international scientific meetings), or other support (such as for travel, education, and publication) from NovoNordisk, Sanofi, Mylan, Merck, Pfizer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Bayer, Zealand, Intarcia, Intercept, Johnson & Johnson, Altimmune, TARGETPharma, Valeritas, Health Monitor, Medscape WebMD, The Learning Institute, and TMIO. PS received grants (paid to their institution) from the National Health and Medical Research Council and received honoraria and other support (such as for travel, education, and publication) from Novo Nordisk. RVC received grants (paid to their institution) from Johnson & Johnson Medical and Medtronic, received honoraria from Johnson & Johnson Medical, Medtronic, Janssen Pharmaceutical, Novo Nordisk, and Abbott, and participated in advisory boards for Bariteck and GI Dynamics. CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Glia, and Boehringer Ingelheim. CWlR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He was the Chief Medical Officer and Director of the Medical Device Division of Keyron in 2011. Both of these were unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. CWlR was gifted stock holdings in September, 2021, and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.",

year = "2022",

month = jun,

day = "11",

doi = "10.1016/S0140-6736(22)00890-X",

language = "English (US)",

volume = "399",

pages = "2189--2190",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10342",

}

TY - JOUR

T1 - Obesity definition for personalised treatment of type 2 diabetes Authors’ reply

AU - Lingvay, Ildiko

AU - Sumithran, Priya

AU - Cohen, Ricardo V.

AU - Roux, Carel W.le

N1 - Funding Information: IL received grants (paid to their institution), consulting fees, other payments (including for participation in meetings, such as steering committees; advisory boards; and presentations at national and international scientific meetings), or other support (such as for travel, education, and publication) from NovoNordisk, Sanofi, Mylan, Merck, Pfizer, Boehringer Ingelheim, Eli Lilly, AstraZeneca, Bayer, Zealand, Intarcia, Intercept, Johnson & Johnson, Altimmune, TARGETPharma, Valeritas, Health Monitor, Medscape WebMD, The Learning Institute, and TMIO. PS received grants (paid to their institution) from the National Health and Medical Research Council and received honoraria and other support (such as for travel, education, and publication) from Novo Nordisk. RVC received grants (paid to their institution) from Johnson & Johnson Medical and Medtronic, received honoraria from Johnson & Johnson Medical, Medtronic, Janssen Pharmaceutical, Novo Nordisk, and Abbott, and participated in advisory boards for Bariteck and GI Dynamics. CWlR reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Glia, and Boehringer Ingelheim. CWlR is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He was the Chief Medical Officer and Director of the Medical Device Division of Keyron in 2011. Both of these were unremunerated positions. CWlR was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. The product has only been tested in rodents and none of Keyron's products are currently licensed. They do not have any contracts with other companies to put their products into clinical practice. No patients have been included in any of Keyron's studies and they are not listed on the stock market. CWlR was gifted stock holdings in September, 2021, and divested all stock holdings in Keyron in September, 2021. He continues to provide scientific advice to Keyron for no remuneration.

PY - 2022/6/11

Y1 - 2022/6/11

UR - http://www.scopus.com/inward/record.url?scp=85131674476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131674476&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(22)00890-X

DO - 10.1016/S0140-6736(22)00890-X

M3 - Letter

C2 - 35691319

AN - SCOPUS:85131674476

SN - 0140-6736

VL - 399

SP - 2189

EP - 2190

JO - The Lancet

JF - The Lancet

IS - 10342

ER -

Obesity definition for personalised treatment of type 2 diabetes Authors’ reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this